Prevalent herpes simplex virus type 2 infection is associated with altered vaginal flora and an increased susceptibility to multiple sexually transmitted infections

Journal of Infectious Diseases

Volumn 196, Issue 11, 2007, Pages 1692-1697

  Kaul, Rupert ^a,b,d,h   Nagelkerke, Nico J ^e,f   Kimani, Joshua ^a,e   Ngugi, Elizabeth ^a   Bwayo, Job J ^a   MacDonald, Kelly S ^b,c   Rebbaprgada, Anu ^b   Fonck, Karolien ^a,g   Temmerman, Marleen ^a,g   Ronald, Allan R ^e   Moses, Stephen ^e   Bossen, Bolette ⁱ   Kamunyo, Grace ⁱ   Wanguru, Ruth ⁱ   Mwakisha, Rachel ⁱ   Waithira, Grace ⁱ   Nganga, Daniel ⁱ   Nyambogo, Cornelius ⁱ   Ombette, John ⁱ   Njeri, Jane ⁱ   Onyango, Isaiah ⁱ   Li, Bing ⁱ   Malonza, Isaac ⁱ   Maclean, Ian ⁱ   Mwangi, Francis ⁱ   Saskin, Refik ⁱ   Strauss, Judy ⁱ   Kariuki, Samuel ⁱ   more..

^a UNIVERSITY OF NAIROBI   (Kenya)

^b UNIVERSITY OF TORONTO   (Canada)

^c MOUNT SINAI HOSPITAL   (Canada)

^d UNIVERSITY HEALTH NETWORK   (Canada)

^e UNIVERSITY OF MANITOBA   (Canada)

^f UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

^g GHENT UNIVERSITY   (Belgium)

^h UNIVERSITY OF TORONTO   (Canada)

ⁱ NONE

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; PLACEBO;

ADULT; ARTICLE; CHLAMYDIA TRACHOMATIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DOUBLE BLIND PROCEDURE; FEMALE; GENITAL HERPES; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 2; HUMAN; MAJOR CLINICAL STUDY; MORBIDITY; NEISSERIA GONORRHOEAE; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SEXUALLY TRANSMITTED DISEASE; SYPHILIS; TREPONEMA PALLIDUM; TRICHOMONAS VAGINALIS; VAGINA FLORA; VAGINITIS; CHLAMYDIASIS; GONORRHEA; INCIDENCE; ISOLATION AND PURIFICATION; KENYA; MICROBIOLOGY; MIDDLE AGED; PROSPECTIVE STUDY; PROSTITUTION; VAGINA; VAGINA CANDIDIASIS; VIROLOGY;

ADULT; CANDIDIASIS, VULVOVAGINAL; CHLAMYDIA INFECTIONS; DISEASE SUSCEPTIBILITY; FEMALE; GONORRHEA; HERPES GENITALIS; HERPESVIRUS 2, HUMAN; HUMANS; INCIDENCE; KENYA; MIDDLE AGED; PREVALENCE; PROSPECTIVE STUDIES; PROSTITUTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEXUALLY TRANSMITTED DISEASES; SYPHILIS; TRICHOMONAS VAGINITIS; VAGINA; VAGINOSIS, BACTERIAL;

EID: 38449118740     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/522006     Document Type: Article

References (25)

1. Freeman EE, Weiss HA, Glynn JR, Cross PL, Whitworth JA, Hayes RJ. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS 2006; 20:73-83.
2. Weiss H. Epidemiology of herpes simplex virus type 2 infection in the developing world. Herpes 2004; 11(Suppl 1):24A-35A.
3. Wald A. Herpes simplex virus type 2 transmission: risk factors and virus shedding. Herpes 2004; 11(Suppl 3):130A-37A.
4. Wald A, Corey L. How does herpes simplex virus type 2 influence human immunodeficiency virus infection and pathogenesis? J Infect Dis 2003; 187:1509-12.
5. Corey L, Wald A, Celum CL, Quinn TC. The effects of herpes simplex virus-2 on HIV-1 acquisition and transmission: a review of two overlapping epidemics. J Acquir Immune Defic Syndr 2004; 35:435-45.
6. Rebbapragada A, Wachihi C, Pettengell C, et al. Negative mucosal synergy between Herpes simplex type 2 and HIV in the female genital tract. AIDS 2007; 21:589-98.
7. Muenzner P, Naumann M, Meyer TF, Gray-Owen SD. Pathogenic Neisseria trigger expression of their carcinoembryonic antigen-related cellular adhesion molecule 1 (CEACAM1; previously CD66a) receptor on primary endothelial cells by activating the immediate early response transcription factor, nuclear factor-kappaB. J Biol Chem 2001; 276:24331-40.
8. Corbett EL, Steketee RW, ter Kuile FO, Latif AS, Kamali A, Hayes RJ. HIV-1/AIDS and the control of other infectious diseases in Africa. Lancet 2002; 359:2177-87.
9. Cherpes TL, Meyn LA, Krohn MA, Lurie JG, Hillier SL. Association between acquisition of herpes simplex virus type 2 in women and bacterial vaginosis. Clin Infect Dis 2003; 37:319-25.
10. Wiesenfeld HC, Hillier SL, Krohn MA, Landers DV, Sweet RL. Bacterial vaginosis is a strong predictor of Neisseria gonorrhoeae and Chlamydia trachomatis infection. Clin Infect Dis 2003; 36:663-68.
11. Kaul R, Kimani J, Nagelkerke NJ, et al. Monthly antibiotic chemoprophylaxis and incidence of sexually transmitted infections and HIV-1 infection in Kenyan sex workers: a randomized controlled trial. JAMA 2004; 291:2555-62.
12. Kaul R, Kimani J, Nagelkerke NJ, et al. Risk factors for genital ulcerations in Kenyan sex workers: the role of human immunodeficiency virus type 1 infection. Sex Transm Dis 1997; 24:387-92.
13. Kaul R, Kimani J, Nagelkerke NJ, et al. Reduced HIV risk-taking and low HIV incidence after enrollment and risk- reduction counseling in a sexually transmitted disease prevention trial in Nairobi, Kenya. J Acquir Immune Defic Syndr 2002; 30:69-72.
14. Schwebke JR, Desmond RA. A randomized trial of the duration of therapy with metronidazole plus or minus azithromycin for treatment of symptomatic bacterial vaginosis. Clin Infect Dis 2007; 44:213-19.
15. Adams EJ, Charlett A, Edmunds WJ, Hughes G. Chlamydia trachomatis in the United Kingdom: a systematic review and analysis of prevalence studies. Sex Transm Infect 2004; 80:354-62.
16. Ouedraogo A, Nagot N, Vergne L, et al. Impact of suppressive herpes therapy on genital HIV-1 RNA among women taking antiretroviral therapy: a randomized controlled trial. AIDS 2006; 20:2305-13.
17. Celum CL, Robinson NJ, Cohen MS. Potential effect of HIV type 1 antiretroviral and herpes simplex virus type 2 antiviral therapy on transmission and acquisition of HIV type 1 infection. J Infect Dis 2005; 191(Suppl 1):S107-14.
18. Kamali A, Kinsman J, Nalweyiso N, et al. A community randomized controlled trial to investigate impact of improved STD management and behavioural interventions on HIV incidence in rural Masaka, Uganda: trial design, methods and baseline findings. Trop Med Int Health 2002; 7:1053-63.
19. Grosskurth H, Mosha F, Todd J, et al. Impact of improved treatment of sexually transmitted diseases on HIV infection in rural Tanzania: randomised controlled trial. Lancet 1995; 346:530-6.
20. Wawer MJ, Gray RH, Sewankambo NK, et al. A randomized, community trial of intensive sexually transmitted disease control for AIDS prevention, Rakai, Uganda. AIDS 1998; 12:1211-25.
21. Cohen CR, Plummer FA, Mugo N, et al. Increased interleukin-10 in the endocervical secretions of women with non-ulcerative sexually transmitted diseases: a mechanism for enhanced HIV-1 transmission? AIDS 1999; 13:327-32.
22. Hedges SR, Barrientes F, Desmond RA, Schwebke JR. Local and systemic cytokine levels in relation to changes in vaginal flora. J Infect Dis 2006; 193:556-62.
23. Yudin MH, Landers DV, Meyn L, Hillier SL. Clinical and cervical cytokine response to treatment with oral or vaginal metronidazole for bacterial vaginosis during pregnancy: a randomized trial. Obstet Gynecol 2003; 102:527-34.
24. Mosca JD, Bednarik DP, Raj NB, et al. Activation of human immunodeficiency virus by herpesvirus infection: identification of a region within the long terminal repeat that responds to a trans-acting factor encoded by herpes simplex virus 1. Proc Natl Acad Sci U S A 1987; 84:7408-12.
25. Nilsen A, Myrmel H. Changing trends in genital herpes simplex virus infection in Bergen, Norway. Acta Obstet Gynecol Scand 2000; 79:693-6.